Please login to the form below

Not currently logged in
Email:
Password:

Oliver Rausch to lead translational research partnership efforts at NIHR

Has experience at UCB, GSK and Cellzome

NIHR Dr Oliver RauschDr Oliver Rausch has been appointed programme director of the UK's National Institute for Health Research translational research partnerships.

As part of the NIHR's Office for Clinical Research Infrastructure (NOCRI), the partnerships was created to support collaboration between industry, the NHS and academia in early and exploratory research for products with the potential to have a direct effect on improving healthcare.

Efforts currently cover two areas, inflammatory respiratory disease and joint and related inflammatory diseases, both of which shall be overseen by Dr Rausch.

He brings industry experience to the role having spent the past 15 years working at pharma companies across Europe.

Most recently, he was VP biology at Cellzome, and he has further experience as director, new chemical entities biology at UCB and as an investigator with GlaxoSmithKline (GSK).

Prior to joining the industry, Dr Rausch was a postdoctoral scientist at the Institute of Cancer Research in London.

“Oliver's appointment will strengthen the development of the Partnerships and underpins NOCRI's commitment to clear and streamlined access to the UK's world-leading clinical research infrastructure,” said Mark Samuels, managing director of NOCRI.

14th September 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics